The FDA is amplifying a recall from Medtronic for its acid reflux testing system, after the company said it received 33 ...

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 ...

Novartis is penning a four-year pact with ProFound Therapeutics to create new therapeutics for heart disease, with $750 ...

Hummingbird Biosciences could one day feather its nest with up to $290 million if its decision to license a phase 2-ready ...

Invivyd has touted its follow-up to the FDA-authorized monoclonal antibody Pemgarda as potentially offering better protection against COVID-19 than available vaccines. | Invivyd has touted its ...

Alto Neuroscience’s phase 2 depression trial has missed its primary efficacy endpoint, as patients on the drug candidate fared no better on a measure of alertness and mood than their peers on placebo.

Cosmo Pharmaceuticals aims to make the colonoscopy a little more up close and personal, for providers anyway, by connecting ...

While the IPO landscape remains icy, Minovia Therapeutics is skating into the market using a special purpose acquisition ...

The FDA is shutting the door to imports of certain endoscope hardware manufactured by Olympus, saying that a production site in Japan has failed to meet quality requirements. | The FDA is shutting the ...

Bayer-owned BlueRock Therapeutics is laying off 50 employees and shuttering its research labs in Cambridge, Massachusetts, in ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader ...